Periodontitis is a type of disease that causes infections in gums and other tissues that support the teeth. The gums pull away from the teeth and form pockets. There are several risk factors associated with periodontitis such as smoking, metabolic disease, hormonal changes in women and girls, other illness such as HIV (human acquired immunodeficiency syndrome) and cancer, and certain medications that reduces the flow of saliva. Periodontitis can be symptomatized by bad breath, loose teeth, painful chewing, bleeding gums, swollen gums, and sensitive teeth. Geistlich Pharma AG is in the process of developing perioSept(r) as a lipopolysaccharide inhibitor for the treatment of periodontitis. Hebei Medical University is in the process of developing GMSCs and collagen scaffolds for the treatment of periodontitis. Some of the companies and universities having the pipeline of periodontitis include Hebei Medical University, Geistlich Pharma AG, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.